Researchers at F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have described GTPase KRAS mutant inhibitors, particularly KRAS G12C mutant, reported to be useful for the treatment of cancer.

Guangdong Hec Pharmaceutical Co. Ltd. has disclosed GTPase KRAS (mutant) inhibitors reported to be useful for the treatment of cancer.

Jacobio Pharmaceuticals Co. Ltd. has described GTPase KRAS (mutant) inhibitors reported to be useful for the treatment of cancer.

Incyte Corp. has developed fused tricyclic compounds acting as GTPase KRAS (mutant) inhibitors. As such, they are reported to be useful for the treatment of cancer, inflammation and immunological disorders.

Mirati Therapeutics Inc. has synthesized GTPase KRAS and its mutant inhibitors reported to be useful for the treatment of cancer.

Mirati Therapeutics Inc. has identified compounds acting as GTPase KRAS and/or GTPase KRAS (mutant) inhibitors reported to be useful for the treatment of cancer.

Kumquat Biosciences Inc. has identified GTPase KRAS and KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer, particularly solid tumors and hematological cancer.

Eli Lilly & Co. has identified GTPase KRAS and its mutant inhibitors reported to be useful for the treatment of cancer.

Suzhou Zelgen Biosciences Co. Ltd. has synthesized GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of pancreatic cancer.

Kumquat Biosciences Inc. has described heterocyclic compounds and PROTACs acting as GTPase KRAS (G12D, G12C, G12S and G13D mutant), and/or G12V and wild-type GTPase KRAS inhibitors reported to be useful for the treatment of cancer.